Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
Tax Provision
Adaptimmune Therapeutics PLC
Tax Provision Peer Comparison
Competitive Tax Provision Analysis
Latest Figures & CAGR of Competitors
Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Tax Provision
-$1.3m
|
CAGR 3-Years
-103%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Tax Provision
$25.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Tax Provision
$19k
|
CAGR 3-Years
-91%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Tax Provision
-$1.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-85%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Tax Provision
£5.6m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Tax Provision
-£8.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
See Also
What is Adaptimmune Therapeutics PLC's Tax Provision?
Tax Provision
-1.3m
USD
Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Tax Provision amounts to -1.3m USD.
What is Adaptimmune Therapeutics PLC's Tax Provision growth rate?
Tax Provision CAGR 5Y
-22%
Over the last year, the Tax Provision growth was 47%. The average annual Tax Provision growth rates for Adaptimmune Therapeutics PLC have been -103% over the past three years , -22% over the past five years .